← Back to patent-cliff list
IFM-2427
Tier C — Watch / tradeIFM-2427
Ifm Tre
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NLRP3
Indications (approved)：Coronary artery disease, Cryopyrin蛋白相关周期性综合征, Knee arthritis, 骨髓疾病, COVID-19
Regional status
US
Phase II
2021-09-20
EU
Phase II
2020-05-27
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of IFM-2427?
Approved indications include: Coronary artery disease, Cryopyrin蛋白相关周期性综合征, Knee arthritis, 骨髓疾病, COVID-19.
When does the IFM-2427 patent expire?
No public expiry year is available for IFM-2427 yet; this page updates once verified.
How do I get a quote for IFM-2427 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07